Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals Inc (KALV) is a clinical-stage biopharmaceutical company advancing novel protease inhibitors for rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Our curated collection offers immediate access to KALV's latest press releases, including progress on oral plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema therapies. Track updates across all development phases – from preclinical research to late-stage trials – while staying informed about partnership announcements and financial disclosures.
Key coverage areas include clinical trial results, FDA communications, intellectual property developments, and scientific presentations. The resource is particularly valuable for monitoring KALV's Factor XIIa inhibitor program and comparative effectiveness data against existing therapies.
Bookmark this page for real-time updates on KalVista's innovative pipeline and regulatory progress. For comprehensive tracking of this clinical-stage innovator's journey in protease inhibition therapeutics, we recommend checking back regularly.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented Phase 2 data for KVD900 at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. KVD900 is an oral treatment for hereditary angioedema (HAE) that demonstrated rapid absorption, with significant symptom relief observed faster than placebo (1.6 hours vs 9.0 hours, p<0.0001). The findings suggest KVD900 could significantly improve patient outcomes during HAE attacks. The data also indicates strong agreement between Patient Global Impression of Change and other reported outcomes, underscoring its clinical relevance.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that its compensation committee granted inducement options to purchase 23,000 shares of common stock to six newly-hired employees on November 3, 2021. The options have an exercise price of $18.22 per share, equal to the closing price on the grant date. Vesting occurs over four years, with one-fourth vesting on the first anniversary and the rest monthly over three years. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, specifically targeting HAE and DME.
KalVista Pharmaceuticals (NASDAQ: KALV) announced on October 1, 2021, the grant of inducement options to six newly-hired employees, allowing them to purchase a total of 40,000 shares of common stock at an exercise price of $17.33, which matches the stock's closing price on the grant date. The options will vest over four years, with one-fourth vesting on the one-year anniversary and the remainder vesting monthly thereafter. These grants comply with Nasdaq Listing Rule 5635(c)(4), highlighting KalVista's commitment to incentivizing new talent.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced participation in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 8:40 a.m. ET. A live webcast will be accessible on their website, with an audio archive available for 30 days post-event. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, with significant products like KVD900 for hereditary angioedema (HAE) and KVD001 for diabetic macular edema (DME) in clinical trials.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced the lifting of the clinical hold on its Phase 2 trial for KVD824, intended for the oral prophylactic treatment of hereditary angioedema (HAE). The FDA's approval allows the company to initiate U.S. site activities for the KOMPLETE trial, which aims to enroll 48 patients across 30 sites in 13 countries. Previous studies indicated KVD824 maintained necessary plasma concentrations with no serious adverse events reported. The trial's primary endpoint focuses on the rate of HAE attacks during treatment.
KalVista Pharmaceuticals (KALV) announced operational progress and financial results for the fiscal quarter ending July 31, 2021. They are advancing the Phase 2 KOMPLETE clinical trial for KVD824 and have scheduled an FDA End-of-Phase 2 meeting for KVD900, aiming to initiate a Phase 3 study soon. Financially, the company reported no revenue, increased R&D expenses of $13.7 million, and a net loss of $16.1 million. Cash reserves decreased to $230.6 million, primarily due to higher operating costs.
KalVista Pharmaceuticals (NASDAQ: KALV) granted inducement options for 43,000 shares to five new employees on September 1, 2021. The options have an exercise price of $20.76 per share, matching the stock's closing price on the grant date. Vesting occurs gradually over four years. KalVista is focused on developing small molecule protease inhibitors for unmet medical needs, notably in hereditary angioedema and diabetic macular edema. The company is advancing multiple clinical trials, including KVD900 for HAE.
KalVista Pharmaceuticals (NASDAQ: KALV) announced significant progress in the Phase 2 clinical trial (KOMPLETE) for KVD824, targeting oral prophylactic treatment of hereditary angioedema (HAE). Regulatory approvals have been obtained in Canada, Australia, and the UK, with patient enrollment expected to commence this quarter. The trial will evaluate various doses of KVD824 against a placebo over 12 weeks. So far, 121 patients have been treated with KVD824, demonstrating a favorable safety profile.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of 20,000 inducement stock options to four newly-hired employees as part of their employment agreement on August 3, 2021. The options have an exercise price of $20.65 per share, aligning with the closing price on the grant date. Vesting occurs in stages, with one-fourth vesting after one year and the rest monthly over three years. KalVista focuses on developing small molecule protease inhibitors for serious diseases, including hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals (KALV) released its operational update and financial results for the fiscal year ending April 30, 2021. Notable progress includes positive Phase 2 results for KVD900, with a Phase 3 program review set with the FDA. However, no revenue was reported for the year, compared to $12.7 million in the previous year, due to the expiration of the Merck Option Agreement. The net loss increased to $46.2 million, primarily from R&D spending and lack of revenue. Cash reserves improved to $248.9 million after a successful public offering in February 2021.
FAQ
What is the current stock price of Kalvista Pharm (KALV)?
What is the market cap of Kalvista Pharm (KALV)?
